FIELD: pharmacology.
SUBSTANCE: pharmaceutical lyophilized preparation, including: botulinum toxin, polysorbate, and methionine, and one or more components selected from the group consisting of sugar, sugar alcohol and ionic compound taken at a specific ratio. The ionic compound selected from sodium chloride, sodium phosphate, ammonium phosphate, magnesium sulfate, sodium acetate, sodium succinate, sodium propionate and potassium phosphate, where the drug does not contain albumin and where the botulinum toxin stability is supported for at least 30 days at 40°C and 70% relative humidity (versions).
EFFECT: compositions allow to maintain stability and activity of the preparation under high temperature conditions.
11 cl, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LYOPHILISED PREPARATION OF BOTULINUM TOXIN | 2012 |
|
RU2574011C2 |
| LIQUID COMPOSITION STABILIZING BOTULINUM TOXIN | 2019 |
|
RU2812790C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE | 2011 |
|
RU2682720C2 |
| COMPOSITION FOR PROTEIN PHARMACEUTICAL PREPARATION WITH NO ADDED HUMAN SERUM ALBUMIN (HSA) | 2004 |
|
RU2491927C2 |
| LIQUID PHARMACEUTICAL COMPOSITION OF BOTULINUM TOXIN | 2008 |
|
RU2440825C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| AQUEOUS SOLUTION OF FACTOR VIII AT DECREASED OXYGEN CONCENTRATION | 1994 |
|
RU2142290C1 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| FSH STABILISATION | 2011 |
|
RU2574012C2 |
| STABLE LIQUID ETANERCEPT COMPOSITION | 2012 |
|
RU2575619C2 |
